Nonimmune Chronic Idiopathic Neutropenia of Adults — Comprehensive Research Report

1. Disease Information

Overview and terminology (a critical naming caveat)

"Nonimmune Chronic Idiopathic Neutropenia of Adults" (NI‑CINA) names two overlapping but distinct concepts in the literature, and curators should be careful not to conflate them:

1. OMIM #607847 "NEUTROPENIA, NONIMMUNE CHRONIC IDIOPATHIC, OF ADULTS" — a specific, rare, autosomal dominant Mendelian entity caused by a heterozygous missense mutation (N382S) in GFI1 (Growth Factor Independent 1 transcriptional repressor), reported in a single large multigenerational kindred by Person et al. (2003) (Nature Genetics; PubMed 12778173). This is the entity MONDO:0011922 formally maps to.
2. "Chronic Idiopathic Neutropenia" (CIN) as a clinical syndrome — a much more commonly described, acquired, adult-onset, immune-microenvironment-mediated neutropenia (Papadaki and colleagues, University of Crete, and others), affecting a substantial minority of the general adult population, with no identified monogenic cause in the vast majority of cases. Confusingly, despite the "nonimmune" label, contemporary mechanistic work (see §6) shows this syndrome is driven by local bone-marrow T-lymphocyte/cytokine-mediated immune suppression of granulopoiesis — it is "nonimmune" only in the narrower sense of lacking demonstrable anti-neutrophil autoantibodies against circulating/mature neutrophils, distinguishing it from classic autoimmune neutropenia (AIN).

Most of the epidemiological, mechanistic, natural-history, and treatment literature available (and cited below) is about sense 2 (the clinical syndrome), because the GFI1 kindred (sense 1) is a single reported family. A curator populating a KB entry under MONDO:0011922 should decide explicitly whether the entry models the GFI1 monogenic disorder, the broader acquired clinical syndrome, or both with clear differentiation — this is a genuine lump/split judgment call, not a research gap that more literature searching will resolve.

Key identifiers

• MONDO: 0011922
• OMIM: #607847 (omim.org/entry/607847)
• Orphanet: ORPHA:2688 (orpha.net/en/disease/detail/2688)
• GARD (NIH): Disease ID 16605
• ICD-10-CM: D70.8 (Other neutropenia) is the most specific code for a defined idiopathic/chronic neutropenia; D70.9 (Neutropenia, unspecified) is used when no further specification is coded (icd10data.com D70)
• Causal gene (GFI1-associated form): GFI1, HGNC:4238, OMIM *600871

Synonyms

• NI-CINA
• Adult idiopathic neutropenia
• Chronic idiopathic neutropenia (CIN) of adults
• Chronic benign neutropenia of adults (used loosely, though CIN is not formally classified as "benign" congenital neutropenia)

Source of information

Nearly all clinical and mechanistic data derive from aggregated disease-level cohort studies and case series (notably a multi-decade Cretan cohort under H. A. Papadaki, and a recent French prospective CYTOPAN study, NCT05931718), not individual EHR mining. The Person et al. 2003 genetic report derives from a single multigenerational pedigree.

2. Etiology

Disease causal factors

• GFI1-associated monogenic form (OMIM #607847): heterozygous GFI1 c.1145A>G (p.Asn382Ser, N382S) mutation, autosomal dominant, reported in one large kindred with variably mild-to-moderate neutropenia across generations (Person et al. 2003, Nat Genet 33:373-377, PMID 12778173). N382S disrupts GFI1's zinc-finger DNA-binding domain, producing a dominant-negative effect on GFI1 target-gene repression.
• Sporadic/acquired CIN (the more common syndrome): cause remains formally "idiopathic" — no infectious, drug, autoimmune-systemic, or malignant etiology is identifiable. Emerging evidence (see §6) implicates a chronic, low-grade, polyclonal T-lymphocyte-driven inflammatory bone-marrow microenvironment, not a primary marrow stem-cell defect.
• A recent whole-exome sequencing comparison of pediatric non-remitting neutropenia vs. adult CIN (Genetic Landscape study, PMID 40725177, 2025) found candidate rare variants in SPINK5, BRCA1, RELA, and CARD11 in individual cases, and enrichment of rare variants in PTPN22, PSMB9, and MYOF, implicating innate/adaptive immune-regulatory pathways rather than a shared monogenic cause; pediatric and adult cohorts shared no common causal variants, supporting a polygenic/complex rather than Mendelian model for most adult CIN.

Risk factors

Genetic: - Heterozygous GFI1 N382S (family-specific; autosomal dominant) for the OMIM entity. - HLA class II susceptibility: increased frequency of HLA-DRB1*1302 haplotype reported in NI-CINA patients (Papadaki et al., Blood 97:580, ashpublications.org/blood/article/97/2/580) — evidence of an immunogenetic (HLA class II) predisposition to the acquired syndrome. - Age-related clonal hematopoiesis (CHIP): somatic mutations in DNMT3A, TET2, IDH1/2, RNA-splicing genes (SRSF2, ZRSR2), and an ETV6-CHIC2 rearrangement detected in ~19% of tested CIN patients, strongly age-associated (median 68 vs. 51 years in mutated vs. non-mutated, p=0.002) (Scientific Reports 2024, PMID via PMC11412994). TET2 mutations specifically carry a modest independent neutropenic effect (~9%, p=0.012) in general CHIP cohorts.

Environmental/demographic: - Sex: strong female predominance (women:men ≈ 3:2 to as high as 77% female in the largest prospective cohort). - Age: typically diagnosed in adulthood; roughly two-thirds of cases occur between ages 30–59, though the largest reclassification cohort (n=266) spanned ages 19–92 (median 61). - Ancestry: baseline population prevalence differs by ancestry group for "benign ethnic neutropenia," a condition that must be excluded (see Diagnostics); this is now formally reclassified as ADAN (absolute neutrophil count [ANC] Duffy-Associated Neutropenia) in the newest nosology, not part of true CIN.

Protective factors

No specific genetic or environmental protective factors have been established in the literature for this condition; it is not modeled as a disease with known protective alleles or exposures.

Gene-environment interactions

Not characterized specifically for CIN; the leading model is intrinsic bone-marrow immune dysregulation (HLA-linked genetic susceptibility interacting with an unidentified triggering low-grade inflammatory process) rather than a defined exogenous exposure interacting with genotype.

3. Phenotypes

Core hematologic finding

• Chronic neutropenia, defined by most recent series as ANC persistently <1.5 × 10⁹/L on ≥3 occasions over ≥3 months (some define using a lower ULN cutoff, e.g., <1.8 ×10⁹/L, adjusted for ancestry to exclude ADAN/benign ethnic neutropenia).
• Suggested HPO term: HP:0001875 (Neutropenia)
• Severity distribution (French CYTOPAN cohort, n=131): median ANC 0.8 ×10⁹/L; moderate (<1×10⁹/L) in 39%; severe (<0.5×10⁹/L) in 24% (PMC11412994).
• Onset: adult-onset (median age 55–61 years across cohorts), though can be diagnosed earlier.
• Course: chronic, typically stable/non-progressive; a subset show spontaneous partial recovery.

Mucocutaneous/oral phenotypes

• Recurrent aphthous stomatitis — frequent, characteristic feature. HPO: HP:0100279 (Recurrent aphthous stomatitis).
• Exaggerated/severe gingivitis, aggressive periodontitis, premature exfoliation of primary dentition (pediatric-onset overlap syndromes). HPO: HP:0000230 (Gingivitis).
• Recurrent mild bacterial infections (skin, upper respiratory, oral) — generally not life-threatening. HPO candidate: HP:0002718 (Recurrent infections).

Immunologic/laboratory phenotypes

• Increased proportions of activated bone-marrow T-lymphocytes (HLA-DR+, CD25+, CD38+, CD69+, Fas+).
• Immunoglobulin disturbances, lymphopenia, reduced memory B cells.
• Altered monocyte subsets (Bizymi et al., PMC6863791).
• Anti-neutrophil autoantibodies: positive in a substantial minority when tested (56% in one cohort) — presence does not correlate with distinct clinical severity or prognosis, undermining the traditional CIN-vs-AIN dichotomy.
• Splenomegaly (~8%) and lymphadenopathy (~5%) in a minority.
• Autoimmune comorbidities (thyroiditis, Sjögren's syndrome) in ~31% of one cohort — raising the question of whether "isolated" CIN and organ-specific autoimmunity share a predisposing immunogenetic background.

Frequency/severity table (from the largest prospective natural-history cohort, n=131, PMC11412994)

Quality of life

No dedicated disease-specific QoL instrument identified in the literature; general infection burden is low, and the largest natural history study explicitly characterizes the condition as benign with minimal life impact for most patients, aside from anxiety related to chronic laboratory abnormality and periodic hematologic surveillance.

4. Genetic/Molecular Information

Causal gene (Mendelian form)

• GFI1 (Growth Factor Independent 1 transcriptional repressor), HGNC:4238, chromosome 1p22.
• Variant: c.1145A>G, p.Asn382Ser (N382S), heterozygous, missense, located in the C-terminal zinc-finger DNA-binding domain.
• Classification: dominant-negative; disrupts GFI1 DNA binding.
• Mechanism: GFI1 normally represses transcription of ELANE (ELA2, neutrophil elastase). The N382S mutant fails to repress ELANE, and quantitative RT-PCR showed elevated ELA2 expression in myeloid colonies from an affected family member vs. an unaffected relative — mechanistically linking GFI1 and ELANE (the gene mutated in classic severe congenital neutropenia / ELANE-related neutropenia) in a shared pathway (Person et al. 2003, Nature Genetics).
• Functional studies in murine systems confirm that GFI1 disease mutations produce a dominant-negative block to granulopoiesis via murine colony-stimulating factor–responsive assays (PMID 18328744).

Somatic/clonal findings in the acquired syndrome

• Clonal hematopoiesis detected in ~19% of a genotyped cohort (n=36): DNMT3A, TET2, IDH1, and an ETV6-CHIC2 rearrangement, VAF range 4.6–18.8%.
• Longitudinal studies show these clones are generally stable over time with limited VAF expansion (P836 abstract, PMC9430755).
• Clonal hematopoiesis (CH) confers markedly increased relative risk (RR ≈ 31.24) for progression to overt MDS/AML compared with non-clonal CIN, particularly with IDH1/2, splicing-gene (SRSF2, ZRSR2), or combined age-related CH gene mutations, and when VAF >10%.
• No progression to myeloid neoplasm was observed during the follow-up period of the largest prospective natural history study, despite the presence of clonal mutations — underscoring that CH in this context is a risk marker requiring surveillance, not a diagnostic pivot to malignancy at baseline.
• No shared causal genetic variant was found between pediatric non-remitting neutropenia and adult CIN in a comparative WES study, and candidate immune-regulatory gene variants (SPINK5, BRCA1, RELA, CARD11, PTPN22, PSMB9, MYOF) were individually rare, supporting complex/polygenic rather than monogenic causation for most adult CIN (PMID 40725177).

Allele frequency / population genetics

No population allele-frequency data are available for the GFI1 N382S variant beyond the single reported kindred (not present in large population databases such as gnomAD, consistent with a private, family-specific variant).

Epigenetic information

• Abnormal, age-inappropriate telomere shortening of peripheral-blood mononuclear cells and granulocytes has been demonstrated in CIN patients, with significantly lower telomerase activity frequency vs. controls, and granulocyte telomere length correlating with ANC (Pavlaki et al. 2012, Haematologica 97:743-750, PMC3342978). This suggests replicative/senescence stress on the granulocytic compartment, likely secondary to chronic immune-mediated marrow suppression rather than a primary telomere-biology disorder.

5. Environmental Information

No specific toxin, occupational, radiation, or infectious agent has been established as causal for CIN; by definition, secondary causes (drugs, infections, known autoimmune/rheumatologic disease, malignancy) are excluded prior to diagnosis. Environmental/lifestyle contributions are not characterized in the literature reviewed; this remains an area without mechanistic data (a legitimate knowledge gap to record rather than a search failure).

6. Mechanism / Pathophysiology

Ordered causal chain (acquired/sporadic CIN — the dominant mechanistic model)

1. An HLA class II-linked immunogenetic predisposition (notably increased frequency of HLA-DRB1*1302) predisposes to an unidentified triggering process that establishes a localized, low-grade chronic inflammatory reaction within the bone-marrow microenvironment — inferred from HLA association studies rather than directly observed at the trigger step.
2. This inflammatory state leads to activation and clonal/oligoclonal expansion of CD3+ T-lymphocytes within the bone marrow, marked by increased HLA-DR+, CD25+, CD38+, CD69+, and Fas+ expression on the T-cell fraction (demonstrated directly by immunophenotyping of marrow aspirates).
3. Activated marrow T-lymphocytes (not CD14+ monocyte/macrophages) produce myelosuppressive cytokines — IFN-γ, Fas-ligand, TNF-α (and soluble TNF-RI), IL-1β, IL-6, IL-8, RANTES/CCL5, and TGF-β1 — demonstrated by cytokine profiling of bone-marrow stromal/mononuclear supernatants, with levels correlating with neutropenia severity.
4. These cytokines result in Fas-mediated apoptosis of CD34+/CD33+ myeloid progenitor cells, evidenced by a low percentage of CD34+/CD33+ cells associated with accelerated apoptosis and Fas overexpression in that compartment, and by an inverse correlation between bone-marrow stromal TNF-α production and progenitor cell numbers (directly demonstrated: Papadaki et al., Blood 101:2591-2600, PMID 12517813).
5. Accelerated progenitor apoptosis causes impaired granulocytopoiesis — reduced myeloid colony formation in vitro and (in a subset) a late maturation-arrest pattern on bone-marrow morphology, though whether the arrest reflects a genuine terminal differentiation block or increased peripheral release of mature cells from marrow remains unresolved (inferred/uncertain, per the largest series' own characterization).
6. Chronically stressed, apoptosis-prone granulocytic precursors show premature replicative senescence, reflected in abnormal telomere shortening and reduced telomerase activity of granulocytes, correlating with ANC — a downstream cellular consequence rather than an independent causal branch.
7. The net effect manifests clinically as persistent peripheral neutropenia with recurrent mild mucosal/bacterial infections and aphthous stomatitis.
8. Branch — clonal hematopoiesis overlay: in a subset of (typically older) patients, age-related somatic mutations (DNMT3A, TET2, IDH1/2, splicing genes) arise independently in hematopoietic stem/progenitor cells within this chronically stressed, cytokine-rich marrow niche; most clones remain stable, but higher-risk mutations (IDH1/2, spliceosome genes, VAF >10%) predispose to eventual clonal evolution toward MDS/AML — a distinct, age-dependent risk pathway layered on top of the primary immune-mediated mechanism rather than its direct consequence.

GFI1-associated (Mendelian) branch, mechanistically distinct: heterozygous dominant-negative GFI1 N382S impairs GFI1's transcriptional repression of its target genes, in particular derepressing ELANE (neutrophil elastase) expression in myeloid progenitors, which disrupts normal granulocytic differentiation — paralleling (but molecularly distinct from) the ELANE-mutant mechanism of classic severe congenital neutropenia. Murine Gfi1-null models independently confirm that loss of Gfi1 function blocks granulocytic maturation, causing accumulation of an atypical immature myelomonocytic population, severe neutropenia, and relative monocytosis.

Molecular pathways

• GFI1 → ELANE repression axis (GFI1 as an upstream transcriptional repressor of neutrophil elastase; suggested GO term: GO:0030851, granulocyte differentiation; also GO:0045892, negative regulation of DNA-templated transcription).
• Fas/FasL apoptotic signaling in myeloid progenitors (GO:0007165 signal transduction; GO:0006915 apoptotic process; GO:0036462 TRAIL-activated apoptotic signaling pathway is a related but not identical pathway — Fas pathway is more precisely GO:0097191, extrinsic apoptotic signaling pathway).
• TNF-α / TNFR1 signaling suppressing granulopoiesis.
• IFN-γ–JAK/STAT signaling in the marrow T-cell compartment.

Cellular processes

• Increased apoptosis of CD34+/CD33+ myeloid progenitors (GO:0006915 apoptotic process; GO:0043069 negative regulation of programmed cell death is inversely relevant).
• T-lymphocyte activation (GO:0042110 T cell activation).
• Impaired granulocyte colony formation / granulocytopoiesis (GO:0030851).
• Cellular senescence of the granulocytic lineage, reflected by telomere attrition (GO:0090399 replicative senescence).

Protein dysfunction

• GFI1 N382S: loss of normal zinc-finger DNA-binding function → dominant-negative transcriptional dysregulation (loss of repressor activity at target loci, notably ELANE).

Immune system involvement

Central to the acquired form: bone-marrow-localized T-cell-mediated immune dysregulation causing paracrine myelosuppression (not classic autoantibody-mediated peripheral neutrophil destruction, which instead characterizes primary autoimmune neutropenia, AIN — a related but formally distinct diagnosis in current nosology).

Tissue damage mechanisms

Cytokine-driven apoptosis is the principal damage mechanism (no fibrosis or necrosis reported as primary features; marrow fibrosis grade MF-1/2 was noted incidentally in 16% of one large cohort but is not considered a defining pathophysiologic feature).

Molecular profiling

• Cytokine/transcriptomic profiling of bone-marrow stromal and mononuclear cell supernatants: elevated IL-1β, IL-6, TGF-β1, IL-8, RANTES/CCL5, TNF-α, sTNF-RI (Papadaki et al., multiple studies).
• Whole-exome sequencing in a small comparative cohort (25 subjects total) identified candidate rare variants without a shared adult-cohort signature (PMC12295308).
• NGS myeloid gene panels in the largest prospective series (n=36 tested of 266-patient reclassification cohort) identified somatic clonal mutations in 19–7/36 tested patients.

Suggested ontology terms for pathophysiology curation

• GO:0030851 granulocyte differentiation
• GO:0002548 monocyte chemotaxis (context: altered monocyte subsets)
• GO:0006915 apoptotic process
• GO:0042110 T cell activation
• CL:0000094 granulocyte; CL:0000576 monocyte; CL:0000084 T cell; CL:0000838 lineage-negative hematopoietic progenitor cell (myeloid progenitor, CD34+/CD33+)
• CL:0002191 granulocyte monocyte progenitor cell

7. Anatomical Structures Affected

• Primary organ: bone marrow (UBERON:0002371) — site of the T-cell/cytokine-mediated myelosuppression and impaired granulocytopoiesis.
• Secondary/peripheral: peripheral blood (UBERON:0000178) — site of the resultant neutropenia; oral mucosa (UBERON:0006920) — site of recurrent aphthous stomatitis and gingivitis; spleen (UBERON:0002106) — mild splenomegaly in a minority.
• Cellular targets: myeloid progenitor cells / granulocyte-monocyte progenitors (CD34+/CD33+) in bone marrow; mature circulating neutrophils (target of autoantibodies in the antibody-positive subset); bone-marrow T-lymphocytes (site of aberrant activation, the proximate immune effector).
• Subcellular: no specific organelle-level pathology reported; apoptotic (mitochondrial/Fas-extrinsic) pathway activation in progenitor cells is implicated at the biochemical level.
• Laterality: not applicable (systemic hematologic disorder).

8. Temporal Development

• Onset: adult-onset by definition; median age at diagnosis 55–61 years across the largest cohorts, though range spans 19–93 years.
• Onset pattern: insidious/chronic; typically detected incidentally on routine complete blood count rather than through acute symptomatic presentation.
• Course: chronic and generally stable, non-progressive in the majority; a subset shows spontaneous partial recovery of ANC over time regardless of anti-neutrophil antibody status.
• Progression: low overall rate of clinical worsening; infection frequency does not correlate with baseline neutropenia severity, antibody status, or demographics in the largest longitudinal study.
• Critical branch point: presence and molecular class of clonal hematopoiesis (IDH1/2, spliceosome genes, VAF>10%) identifies a subset at meaningfully higher risk of eventual clonal evolution to MDS/AML — this is the key prognostic inflection point identified in recent literature, distinguishing "benign stable CIN" from "CIN with high-risk CH" as a quasi-distinct disease trajectory.
• Remission: spontaneous, partial ANC normalization reported in some patients over years of follow-up; no treatment-induced remission is described as curative (G-CSF is supportive, not disease-modifying).

9. Inheritance and Population

Epidemiology

• Prevalence: the classic Cretan population screening study found 8.23% of an apparently healthy adult population fulfilled CIN diagnostic criteria on repeated testing (Ann Hematol, PMID 10466440) — a strikingly high figure reflecting broad screening criteria in a specific population, and should be treated cautiously as an upper-bound/local estimate rather than a global prevalence. Some general sources cite population estimates around 1% in White and up to 5% in Black populations for "idiopathic"/benign neutropenia broadly (note: much of the Black-population estimate reflects benign ethnic neutropenia / ADAN, which is now nosologically separated from true CIN in current classification schemes — see §10).
• Incidence: not separately reported as an incidence rate; CIN is typically described via point-prevalence in screened or referred cohorts.

Inheritance (GFI1-associated form)

• Pattern: autosomal dominant.
• Penetrance: appears high within the reported kindred but severity is variable across generations (variable expressivity).
• Anticipation, mosaicism, founder effects: not reported/characterized for this single-family variant.

Inheritance (sporadic CIN)

• Not Mendelian; HLA-DRB1*1302 association indicates a polygenic/immunogenetic susceptibility rather than a single-gene inheritance pattern. A minority of the reclassified large cohort (6.8%) were ultimately characterized as "familial with undefined genetic defect," indicating unresolved heritable components in some cases.

Population demographics

• Sex ratio: strong female predominance, ~3:2 to 77:23 (F:M) across cohorts.
• Age distribution: predominantly middle-aged to older adults (median 55–61 years); ~two-thirds of cases aged 30–59 in earlier series.
• Geographic/ancestry notes: original large descriptive cohorts are heavily Greek/Cretan (single-center, potential ascertainment bias); newer reclassification work (French CYTOPAN cohort) broadens the geographic base. Ancestry-specific normal ANC ranges (relevant to excluding ADAN/benign ethnic neutropenia, historically overrepresented in individuals of African ancestry) must be applied before diagnosing true CIN.

10. Diagnostics

Diagnostic criteria

• ANC persistently <1.5 ×10⁹/L (adjusted for ancestry-specific normal ranges) on ≥3 occasions over a ≥3-month period, with exclusion of drug-induced, infectious, autoimmune-systemic, congenital, and malignant causes.

Laboratory tests

• Serial CBC with differential to establish chronicity and exclude cyclic neutropenia (which requires serial counts 2–3×/week over 6 weeks to detect ~21-day periodicity).
• Anti-neutrophil autoantibody testing (GIFT/GIIFT assays) — recommended in patients with ANC <1×10⁹/L, with re-testing of initially negative results, per current European guidelines cited in the natural-history study.
• Immunoglobulin levels, ANA, and rheumatologic serologies to screen for underlying autoimmune disease.

Bone marrow evaluation

Recommended as part of a "proper" diagnostic workup (per recent guideline-referencing literature): morphology (looking for the late maturation-arrest pattern seen in a subset), flow cytometry, cytogenetics, and immunohistochemistry (IgG/IgM/C3/C4d deposition patterns, reported present in >80% of biopsies in the largest cohort — notably, patients with negative C3 deposition had significantly higher baseline ANC, p<0.01).

Genetic/molecular testing

• NGS myeloid gene panel to detect clonal hematopoiesis (DNMT3A, TET2, IDH1/2, ASXL1, splicing genes, ETV6 rearrangements) — recommended especially in older patients, given prognostic implications for MDS/AML risk.
• Targeted GFI1 (and ELANE) sequencing should be considered when there is a clear autosomal-dominant family history consistent with the Mendelian entity, or overlapping features with congenital neutropenia.
• Newer machine-learning-assisted diagnostic/prognostic tools are emerging from large-cohort reclassification work (Tsaknakis et al., 266-patient cohort, Blood 2025) to better stratify patients labeled CIN into true CIN, CCUS, primary AIN, familial undefined, ADAN, secondary neutropenia, and unrecognized severe congenital neutropenia.

Differential diagnosis (reclassification data from the largest cohort, n=266)

This reclassification data (from Tsaknakis et al., ASH abstract, Blood 2025) is directly relevant to knowledge-base curation: roughly a third of patients historically labeled "CIN" carry a more specific diagnosis on thorough re-evaluation, underscoring that "idiopathic" is a diagnosis of exclusion that shrinks as diagnostic tools improve — a live nosological caveat rather than settled fact.

Screening

No population-level or newborn screening program exists for CIN; diagnosis is reactive, based on incidental or symptom-triggered CBC abnormalities.

11. Outcome/Prognosis

• Mortality: minimal and not disease-attributable — in the largest prospective cohort (n=131, median 3-year follow-up), only 2 deaths occurred (myocardial infarction, colorectal cancer), unrelated to neutropenia.
• Malignant transformation: zero cases of evolution to hematologic malignancy in the largest prospective natural-history cohort despite clonal hematopoiesis findings in a subset; however, retrospective/cross-sectional data on clonal-hematopoiesis-positive CIN patients show a substantially elevated relative risk (~31×) for eventual MDS/AML transformation versus non-clonal CIN, particularly with high-risk mutation classes (IDH1/2, spliceosome genes) or VAF >10%.
• Infection burden: low; grade ≥3 infections occurred in only 10% of patients over 3-year follow-up, with no correlation to neutropenia severity, demographics, or antibody status — an important and somewhat counterintuitive finding, suggesting ANC threshold alone is a poor infection-risk predictor in this specific syndrome (unlike classic congenital/chemotherapy-induced neutropenia).
• Overall characterization: the condition is repeatedly described in the primary literature as a "benign condition without life-threatening infections" warranting extensive hematologic evaluation (including bone marrow assessment) primarily to inform differential diagnosis and identify the clonal-hematopoiesis-positive subset needing surveillance, rather than because the baseline course itself is dangerous.
• Prognostic factors: presence/class of clonal hematopoiesis mutation and VAF; older age (associated with higher CH prevalence); negative marrow C3 deposition (associated with higher baseline ANC, i.e., milder disease).

12. Treatment

Pharmacotherapy

• Granulocyte colony-stimulating factor (G-CSF, filgrastim): the primary specific pharmacologic intervention, but used sparingly in practice — only 4.6% of patients in the largest natural-history cohort received G-CSF, and only 2 patients (of 131) received it chronically, reflecting the generally low infection burden and benign course.
• Dosing: typically initiated at ~3 μg/kg subcutaneously daily, titrated to a target ANC of 1,500–2,000/μL; patients with cyclic/idiopathic neutropenia generally respond at lower doses than those with congenital neutropenia.
• Long-term safety: no loss of efficacy with prolonged use reported; long-term G-CSF use does not appear to independently increase AML risk in this population, though caution/monitoring is still advised given the theoretical concern (relevant NCIT term: NCIT:C1177, Filgrastim; treatment action NCIT:C15986, Pharmacotherapy).
• Corticosteroids/immunosuppressants: current expert recommendation, per the recent natural-history study, is to avoid steroids unless there is a clearly established co-existing autoimmune diagnosis — reflecting the recognition that antibody positivity alone does not warrant immunosuppression given no demonstrated prognostic benefit.
• Ezatiostat (TLK199), a glutathione S-transferase P1-1 inhibitor, has shown case-report efficacy in G-CSF-resistant idiopathic chronic neutropenia (PMC3235963) — an investigational/off-label approach for refractory cases, not a standard-of-care agent.

Surgical/interventional

Not applicable as primary therapy; splenectomy is not indicated for isolated CIN (contrasts with some AIN/hypersplenism-associated cytopenias).

Supportive care

• Dental/oral hygiene surveillance and management of recurrent aphthous stomatitis and gingivitis.
• Antibiotic therapy for documented infections; no evidence supports prophylactic antibiotics in the absence of severe/recurrent infection.

Experimental

Registered trial: CYTOPAN (NCT05931718), the French prospective observational study underlying much of the modern natural-history and immunohistochemistry data cited above.

Treatment strategy

Because infection risk correlates poorly with ANC severity in this specific syndrome, treatment is generally symptom- and infection-triggered rather than ANC-threshold-triggered — a notable departure from management paradigms for congenital or chemotherapy-induced neutropenia, and a point worth explicit note in a KB treatments: block or notes:.

13. Prevention

No primary, secondary, or tertiary prevention strategies are described in the literature, consistent with CIN's idiopathic/immune-microenvironmental etiology and lack of an identified modifiable environmental trigger. Genetic counseling is relevant only for the rare GFI1-associated autosomal dominant kindred (risk assessment for at-risk relatives, prenatal/preimplantation testing not reported as utilized). No vaccination-based, screening-based, or public-health-level prevention approach applies.

14. Other Species / Natural Disease

• Mouse (Mus musculus, NCBITaxon:10090): Gfi1-null mice are severely neutropenic, showing a block in myeloid differentiation with accumulation of an atypical immature myelomonocytic population, absence of mature granulocytes, and relative monocytosis — directly recapitulating the human GFI1-mutant neutropenia phenotype at the level of blocked granulopoiesis (though via null rather than dominant-negative mechanism in most mouse models). Gfi1 knock-in models bearing SCN-associated point mutations further reveal stage-specific Gfi1-dependent checkpoints in myeloid development.
• No naturally occurring veterinary disease analog specific to GFI1-mutant or Papadaki-type immune-mediated adult CIN was identified in this search (distinct from canine cyclic neutropenia/"grey collie syndrome," which is an ELANE-pathway, not GFI1-pathway, disorder and a different clinical entity).
• Orthologous gene: murine Gfi1 (MGI:95662), human GFI1 ortholog, high evolutionary conservation of the zinc-finger repressor domain relevant to the N382S mutation.

15. Model Organisms

Model limitations: the complete Gfi1 knockout is a more severe phenotype than the human heterozygous dominant-negative N382S carrier state (variable, generally milder neutropenia in the reported kindred), and murine models do not capture the T-cell/cytokine-driven immune-microenvironmental mechanism believed to underlie the far more common sporadic/acquired CIN syndrome — there is currently no established animal model for the acquired, HLA-linked, T-cell-mediated form of adult CIN, which is a genuine translational gap rather than an unsearched area.

Summary of Key Citations (PMID-first where available)

• Person RE et al. Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. Nat Genet 2003;33:373-377. PMID 12778173 / Nature Genetics
• Papadaki HA et al. Non-immune chronic idiopathic neutropenia of adult: an overview. Eur J Haematol 2001;66:1-8. PMID 11553265
• Papadaki HA et al. Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells. Blood 2003;101:2591-2600. PMID 12517813
• Papadaki HA et al. Increased frequency of HLA-DRB11302 haplotype in patients with nonimmune chronic idiopathic neutropenia of adults. Blood* 2001;97:580-582. ashpublications.org
• Pavlaki KI et al. Abnormal telomere shortening of peripheral blood mononuclear cells and granulocytes in patients with chronic idiopathic neutropenia. Haematologica 2012;97:743-750. PMC3342978
• Prevalence of chronic idiopathic neutropenia of adults among an apparently healthy population living on the island of Crete. Ann Hematol 1999. PMID 10466440
• Natural history of chronic idiopathic neutropenia of the adult. Sci Rep 2024. nature.com/articles/s41598-024-71719-2 / PMC11412994
• Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood 2015;126:1643-1651. ashpublications.org
• Genetic Landscape of Non-Remitting Neutropenia in Children and Chronic Idiopathic Neutropenia in Adults. 2025. PMID 40725177. PMC12295308
• Tsaknakis et al. Novel diagnostic and prognostic tools for patients with chronic idiopathic neutropenia: Data on a cohort of 266 patients. Blood 2025;146(Suppl 1):623. ashpublications.org
• Long-term dynamics of clonal hematopoiesis in chronic idiopathic neutropenia (CIN). PMC9430755
• Bizymi N et al. Altered Monocyte Subsets in Patients with Chronic Idiopathic Neutropenia. 2019. PMC6863791
• Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice. Leukemia 2018. PMC6326955

Curatorial note on gaps and ambiguities (explicitly flagged, not silently omitted)

1. Scope decision required: whether the dismech entry under MONDO:0011922 should center on the GFI1 monogenic kindred (matching the strict OMIM title), the broad acquired CIN syndrome (matching nearly all available mechanistic/epidemiologic/treatment literature), or both with clear has_subtypes separation — this is a lump/split call, not resolved by further search, and should be checked against docs/explanation/design-decisions.md and the granularity conventions before curation begins.
2. Bone-marrow maturation-arrest pattern: whether it reflects a true terminal differentiation block or increased marrow release of mature cells is explicitly stated as unresolved in the primary literature — should be modeled as a HUMAN_MODEL_MISMATCH/knowledge-gap-flavored uncertainty, not asserted as settled mechanism.
3. No animal model exists for the T-cell/cytokine-driven acquired form — only the Mendelian GFI1 form has a validated murine model; this asymmetry should be reflected honestly in any animal_models: block.
4. Prevalence figures are population/cohort-specific (8.23% Cretan screening cohort vs. more conservative "~1% White/~5% Black" general estimates, the latter partly confounded by ADAN/ethnic-neutropenia inclusion) — a single number should not be asserted without qualifying the source population.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0100279 (1 mention) - the report calls it "Recurrent aphthous stomatitis"; HP calls it Ulcerative colitis
• GO:0030851 (3 mentions) - the report calls it "Impaired granulocyte colony formation / granulocytopoiesis"; GO calls it granulocyte differentiation
• UBERON:0000178 (1 mention) - the report calls it "Secondary/peripheral: peripheral blood"; UBERON calls it blood**

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0001875 (1 mention) - the report calls it "Neutropenia"; HP calls it Decreased total neutrophil count, and lists "Neutropenia" among its other names
• HP:0002718 (1 mention) - the report calls it "Recurrent infections"; HP calls it Recurrent bacterial infections, and lists "Recurrent pyogenic infections" among its other names
• UBERON:0002371 (1 mention) - the report calls it "bone marrow", "Primary organ: bone marrow"; UBERON calls it bone marrow

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• UBERON:0002371 - called "bone marrow", "Primary organ: bone marrow"
• MGI:95662 - called "Gfi1", "Orthologous gene:* murine Gfi1"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.